Bromodomain inhibitors could also be deployed to interrupt another interaction identified in the Nature paper, between SARS-CoV-2 transmembrane envelope protein (E) and BRD2 and/or BRD4. “This potential mechanism of action could be relevant in the context of the secondary immune-related consequences of SARS-CoV-2 infection,” says Andy Conery, director of Functional Genomics at Constellation Pharmaceuticals. Those bromodomain inhibitors already in the clinic include Resverlogix’s apabetalone, in phase 3 trials for cancer and phase 1 for pulmonary arterial hypertension; AbbVie’s ABBV-744, in phase 1 for cancer; and Constellation Pharmaceuticals’ CPI-0610, in phase 2 for cancer.